Interestingly, although the use of SGLT-2 inhibitors reduced the risk of CV death or HHF, as well as HHF, no changes were observed concerning the reduction of CV death and all-cause mortality in patients with T2DM or HF alone. This evidence concerns the gene SLC5A2 and hydrops fetalis.